Soliris 300mg Injection
Rx RequiredSalt Composition: Eculizumab
Expiry Date: 01/2028
Price on Request
Inclusive of all taxes
1 Vial
About The Product
Blood Cancer
Soliris 300mg Injection is a formulation of Eculizumab, a humanized monoclonal antibody. This medicine is used in the treatment of patients diagnosed with myasthenia gravis. This disease is a long-term neuromuscular condition.
Eculizumab is also used in the prevention of red blood cell breakdown. It is indicated to patients weighing above 5 kilograms (11 pounds) to treat various blood disorders. Soliris (Eculizumab) is available in the strength of 300mg as injections for intravenous (IV) use only.
Description
Soliris 300mg Injection contains active ingredient Eculizumab which is a recombinant humanized monoclonal antibody. Doctor prescribes this injection to treat rare blood disorders including paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and generalised myasthenia gravis (gMG).
It acts by blocking the complement protein C5 in the immune system. It should be administered by a doctor or experienced nurse. Don't self administer the injection.
Uses
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Atypical Hemolytic Uremic Syndrome (aHUS)
Generalised Myasthenia Gravis (gMG)
Prevention of Complement-Mediated Organ Damage
Other Rare Complement-Mediated Disorders
Side Effects
Like any other medicine, Soliris 300mg Injection also shows some side effects. Some of the mild ones do not need any medical attention, and they go away as the body adapts to the medicine. It is important to consult your doctor if they persist for a longer time and are deteriorating your health.
Common side effects include:
Headache
Fatigue
Nausea
Diarrhea
Fever or mild chills
Dizziness
Cough or mild shortness of breath
Skin rash or redness at the injection site
How To Use
- Soliris 300mg is available in injection form and is advised to be taken as per the doctor's prescription. It can only be given intravenously by a doctor or nurse under strict medical supervision.
- Taking this Eculizumab injection in the wrong way may give you severe side effects. In case of overdose, contact your healthcare provider or doctor and they will provide you with medical attention.
- Missing or overdosing will impact the overall health of the patients and may also have side effects. So, it is always advisable to follow the prescription of the doctor strictly.
Safety Advice
Avoid the consumption of alcohol while taking Soliris 300mg Injection, as alcohol can decrease the effectiveness of the medicine as well as worsen the symptoms.
Do not take Soliris 300mg Injection without consulting the doctor in case of pregnancy, as it can be unsafe to take it during this period.
Breastfeeding women should discuss the potential risks and benefits of the Soliris 300mg Injection with their healthcare provider before starting treatment.
Soliris 300mg Injection may cause side effects such as dizziness or lack of concentration, which could affect your ability to drive. So it's better to avoid driving.
Share your medical history with the doctor before starting the Soliris 300mg Injection. Do not take it without consulting a doctor if you have any kidney related issue.
Share your medical history with the doctor before starting the Soliris 300mg Injection. Do not take it without consulting a doctor if you have any liver related issue.
Missed Doses
- If you skip a dose of Soliris injection, you must ask your doctor about the best ways to cope with it.
- Your therapy may require rescheduling.
FAQs
Soliris 300mg Injection prescribes this injection to treat rare blood disorders including paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and generalised myasthenia gravis (gMG).
References
Keating, G. M. (2013). Eculizumab: a review of its use in atypical haemolytic uraemic syndrome. Drugs, 73(18), 2053-2066. https://pubmed.ncbi.nlm.nih.gov/24249647/
Gruppo, R. A., & Rother, R. P. (2009). Eculizumab for congenital atypical hemolytic–uremic syndrome. New England Journal of Medicine, 360(5), 544-546. https://pubmed.ncbi.nlm.nih.gov/19179329/
Engel, E. R., & Walter, J. E. (2020). Rituximab and eculizumab when treating nonmalignant hematologic disorders: infection risk, immunization recommendations, and antimicrobial prophylaxis needs. Hematology 2014, the American Society of Hematology Education Program Book, 2020(1), 312-318. https://pubmed.ncbi.nlm.nih.gov/33275746/
Paul, F. (2013). Hope for a rare disease: eculizumab in neuromyelitis optica. The Lancet Neurology, 12(6), 529-531. https://pubmed.ncbi.nlm.nih.gov/23623398/
- Parker, C. J., Kar, S., & Kirkpatrick, P. (2007). Eculizumab. Nature Reviews Drug Discovery, 6(7), 515-516.
Medical Disclaimer
Accurate, reviewed information to support informed healthcare decisions
Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.
The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.
This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.
Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.
.png&w=48&q=75 "Cart"){kind=small}
9655.png&w=48&q=75 "Home"){kind=small}
